ethyl loflazepate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| diazepam derivatives | 1092 | 29177-84-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2 | mg | O |
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Altered state of consciousness | 52.10 | 29.39 | 18 | 932 | 25212 | 63462860 |
| Tongue oedema | 50.11 | 29.39 | 12 | 938 | 4574 | 63483498 |
| Rash maculo-papular | 33.88 | 29.39 | 14 | 936 | 31882 | 63456190 |
| Neuroleptic malignant syndrome | 30.38 | 29.39 | 10 | 940 | 12046 | 63476026 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Altered state of consciousness | 57.18 | 26.31 | 24 | 1524 | 43798 | 79699042 |
| Tongue oedema | 41.76 | 26.31 | 12 | 1536 | 7105 | 79735735 |
| Parkinsonism | 39.20 | 26.31 | 14 | 1534 | 16570 | 79726270 |
| Irritability | 35.87 | 26.31 | 17 | 1531 | 41127 | 79701713 |
| Neuroleptic malignant syndrome | 35.61 | 26.31 | 15 | 1533 | 27544 | 79715296 |
| Suicide attempt | 34.67 | 26.31 | 21 | 1527 | 82911 | 79659929 |
| Mallory-Weiss syndrome | 31.86 | 26.31 | 8 | 1540 | 2844 | 79739996 |
| Intentional overdose | 29.96 | 26.31 | 21 | 1527 | 105939 | 79636901 |
| Patient isolation | 28.13 | 26.31 | 4 | 1544 | 63 | 79742777 |
| Pressure of speech | 27.21 | 26.31 | 6 | 1542 | 1222 | 79741618 |
| Hepatic function abnormal | 26.71 | 26.31 | 17 | 1531 | 73090 | 79669750 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05BA18 | NERVOUS SYSTEM PSYCHOLEPTICS ANXIOLYTICS Benzodiazepine derivatives |
| MeSH PA | D014151 | Anti-Anxiety Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Depressive disorder | indication | 35489007 | |
| Anxiety | indication | 48694002 | |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.28 | acidic |
| pKa2 | 9.89 | acidic |
| pKa3 | 3.83 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D01293 | KEGG_DRUG |
| C0059772 | UMLSCUI |
| CHEBI:31573 | CHEBI |
| CHEMBL1213460 | ChEMBL_ID |
| DB01545 | DRUGBANK_ID |
| C029617 | MESH_SUPPLEMENTAL_RECORD_UI |
| 3299 | PUBCHEM_CID |
| C040581 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4837 | INN_ID |
| VJB5FW9W9J | UNII |
| 24524 | RXNORM |
| 005857 | NDDF |
| 769093001 | SNOMEDCT_US |
| C0099755 | UMLSCUI |
| 71735-10-9 | SECONDARY_CAS_RN |
| 155667 | PUBCHEM_CID |
| Y3R871DUQ5 | UNII |
Pharmaceutical products:
None